Interleukin Inhibitors Market
Segments - by Applications (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, and Others), Types (IL-17, IL-23, IL-1, IL-5, IL-6, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global interleukin inhibitors market size is anticipated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of autoimmune diseases and growing adoption of interleukin inhibitors.
Interleukin (IL) is a group of cytokines which are synthesized by macrophages, monocytes, lymphocytes, and other cells. Interleukin regulate cell motility, cell growth, and cell differentiation. Inside the body there are total fifteen different types of interleukin are present. Interleukin inhibitors are immunosuppressive agents which prevent the action of interleukins. IL inhibitors are used in many conditions such as arthritis (psoriatic and rheumatoid), ankylosing spondylitis, systematic sclerosis, gout, psoriasis, asthma, and eczema.
There is a substantial paradigm shift in the autoimmune diseases treatment over the last few decades. The inclination toward targeted therapies is increasing because of improvement in safety and efficiency of profiles. Patent expiry and raised acceptance of biosimilar in Tumor Necrosis Factor (TNF) inhibitors has increased the market growth. Launching of new products are aided the market growth. For instance, AbbVie, Inc., in 2019, launched Skyrizi (risankizumab-rzaa) for plaque psoriasis treatment. Also, in 2018, Ilumya (tildrakizumab-asmn) was launched by Sun Pharmaceutical Industries Inc. for moderate-to-severe plaque psoriasis.
Due to upcoming launches of late-stage pipeline candidates the demand of interleukin inhibitors is increasing. Expansion of labels of marketed products, for example, Dupixent for atopic dermatitis and Actemra for juvenile idiopathic arthritis are estimated to boost the penetration. Also, ongoing clinical trials are helping IL inhibitors market with their positive outcomes.
Market Trends, Drivers, Restraints, and Opportunities
- Growing awareness about benefits of interleukin inhibitors among physicians and consumers is major factor responsible for the market expansion during the forecast period.
- Increasing favorable initiatives and programs by government for promoting usage of interleukin inhibitors and accessibility to strong pipeline of products are projected to drive the market growth.
- Rising prevalence of autoimmune disorders and other inflammatory diseases and rising number of investigational drugs are anticipated to fuel the growth of the market.
- Increasing FDA approvals for therapies and novel drugs for treatment of chronic inflammatory disease is expected to propel the market growth in coming years.
- Growing presence of targeted therapies because of its efficiency and safety is estimated to drive the market growth during the forecast period.
- High cost of utilization and adoption of treatment in different disease application is major factor that can hamper the market growth.
- Strict regulations and guidelines, and side effects related to this treatment are projected to impede the market growth over the forecast period.
Scope of the Report
The report on the global interleukin inhibitors market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Interleukin Inhibitors Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Applications (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, and Others), Types (IL-17, IL-23, IL-1, IL-5, IL-6, and Others) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Johnson & Johnson Services, Inc., Novartis AG, AbbVie Inc., Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., AstraZeneca, Bausch Health, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., and Teva Pharmaceuticals Industries, Ltd. |
Market Segment Insights
Psoriasis segment is projected to hold a major market share
Based on applications, the interleukin inhibitors market is divided into psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, and others. The psoriasis segment is expected to hold a key share of the market during the forecast period due to strong performances of Stelara, Cosentyx, and Taltz. Favorable reimbursement policies, growing prevalence of diseases, and increasing awareness among consumers are expected to fuel the segment growth.
On the other hand, the psoriatic arthritis segment is anticipated to expand at a rapid pace during the forecast period. Due to upcoming launches of late-stage pipeline products and expansion of labels of existing products specified for Crohn’s disease, ulcerative colitis, and arthritis are major factors responsible for the market growth.
IL-17 segment is expected to grow at a rapid pace
On the basis of types, the interleukin inhibitors market is segmented into IL-17, IL-23, IL-1, IL-5, IL-6, and others. The IL-23 segment dominated the market share and is expected to account for a key share of the market in the coming years due to new entrants and usage of blockbuster drug Stelara. Also, there are other drugs which are added, such as Tremfya in 2017, Ilumya in 2018, and Skyrizi in 2019. Still Stelara is generating largest revenue in spite of its patent expiry in 2023.
However, the IL-17 segment is anticipated to expand at a rapid pace during the forecast period owing to increase in sales of Cosentyx and Taltz. In 2017, a third year of launch, Cosentyx became a blockbuster drug. Launch of Siliq and awaiting approval of bimekizumab are projected to drive the segment growth.
North America is expected to dominate the market
On the basis of regions, the interleukin inhibitors market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to increasing commercial sales of interleukin inhibitors in the U.S. In addition to this, there are some other factors responsible for the regional growth are rise in expenditure of healthcare, local presence of major market players, and favorable government initiatives.
On the other hand, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to economic development, rise in disposable income, growing awareness among consumers, and improvement in infrastructure of healthcare. Developing countries including India, China, and South Korea are projected to boost the segment growth.
Segments
Segments Covered in the Report
The global interleukin inhibitors market has been segmented on the basis of
Applications
- Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Asthma
- Inflammatory Bowel Disease (IBD)
- Others
Types
- IL-17
- IL-23
- IL-1
- IL-5
- IL-6
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Johnson & Johnson Services, Inc.
- Novartis AG
- AbbVie Inc.
- Eli Lilly and Company
- Regeneron Pharmaceuticals, Inc.
- AstraZeneca
- Bausch Health
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc.
- Teva Pharmaceuticals Industries, Ltd.
Competitive Landscape
Key players competing in the interleukin inhibitors market include Johnson & Johnson Services, Inc., Novartis AG, AbbVie Inc., Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., AstraZeneca, Bausch Health, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., and Teva Pharmaceuticals Industries, Ltd.
Major market players are focusing on several business strategies including mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, Eli Lilly and Company is involved in the development of Mirikizumab which is an IL-23 product. It is under phase 3 trial and specified for ulcerative colitis and psoriasis.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Interleukin Inhibitors Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Interleukin Inhibitors Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Interleukin Inhibitors Market - Supply Chain
4.5. Global Interleukin Inhibitors Market Forecast
4.5.1. Interleukin Inhibitors Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Interleukin Inhibitors Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Interleukin Inhibitors Market Absolute $ Opportunity
5. Global Interleukin Inhibitors Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Interleukin Inhibitors Market Size and Volume Forecast by Types
5.3.1. IL-17
5.3.2. IL-23
5.3.3. IL-1
5.3.4. IL-5
5.3.5. IL-6
5.3.6.
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Interleukin Inhibitors Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Interleukin Inhibitors Market Size and Volume Forecast by Applications
6.3.1. Psoriasis
6.3.2. Psoriatic Arthritis
6.3.3. Rheumatoid Arthritis
6.3.4. Asthma
6.3.5. Inflammatory Bowel Disease (IBD)
6.3.6.
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Interleukin Inhibitors Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Interleukin Inhibitors Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Interleukin Inhibitors Demand Share Forecast, 2019-2026
8. North America Interleukin Inhibitors Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Interleukin Inhibitors Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Interleukin Inhibitors Market Size and Volume Forecast by Types
8.4.1. IL-17
8.4.2. IL-23
8.4.3. IL-1
8.4.4. IL-5
8.4.5. IL-6
8.4.6.
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Interleukin Inhibitors Market Size and Volume Forecast by Applications
8.7.1. Psoriasis
8.7.2. Psoriatic Arthritis
8.7.3. Rheumatoid Arthritis
8.7.4. Asthma
8.7.5. Inflammatory Bowel Disease (IBD)
8.7.6.
8.8. Basis Point Share (BPS) Analysis by Applications
8.9. Y-o-Y Growth Projections by Applications
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Interleukin Inhibitors Demand Share Forecast, 2019-2026
9. Latin America Interleukin Inhibitors Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Interleukin Inhibitors Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Interleukin Inhibitors Market Size and Volume Forecast by Types
9.4.1. IL-17
9.4.2. IL-23
9.4.3. IL-1
9.4.4. IL-5
9.4.5. IL-6
9.4.6.
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Interleukin Inhibitors Market Size and Volume Forecast by Applications
9.7.1. Psoriasis
9.7.2. Psoriatic Arthritis
9.7.3. Rheumatoid Arthritis
9.7.4. Asthma
9.7.5. Inflammatory Bowel Disease (IBD)
9.7.6.
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Interleukin Inhibitors Demand Share Forecast, 2019-2026
10. Europe Interleukin Inhibitors Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Interleukin Inhibitors Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Interleukin Inhibitors Market Size and Volume Forecast by Types
10.4.1. IL-17
10.4.2. IL-23
10.4.3. IL-1
10.4.4. IL-5
10.4.5. IL-6
10.4.6.
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Interleukin Inhibitors Market Size and Volume Forecast by Applications
10.7.1. Psoriasis
10.7.2. Psoriatic Arthritis
10.7.3. Rheumatoid Arthritis
10.7.4. Asthma
10.7.5. Inflammatory Bowel Disease (IBD)
10.7.6.
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Interleukin Inhibitors Demand Share Forecast, 2019-2026
11. Asia Pacific Interleukin Inhibitors Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Interleukin Inhibitors Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Interleukin Inhibitors Market Size and Volume Forecast by Types
11.4.1. IL-17
11.4.2. IL-23
11.4.3. IL-1
11.4.4. IL-5
11.4.5. IL-6
11.4.6.
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Interleukin Inhibitors Market Size and Volume Forecast by Applications
11.7.1. Psoriasis
11.7.2. Psoriatic Arthritis
11.7.3. Rheumatoid Arthritis
11.7.4. Asthma
11.7.5. Inflammatory Bowel Disease (IBD)
11.7.6.
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Interleukin Inhibitors Demand Share Forecast, 2019-2026
12. Middle East & Africa Interleukin Inhibitors Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Interleukin Inhibitors Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Interleukin Inhibitors Market Size and Volume Forecast by Types
12.4.1. IL-17
12.4.2. IL-23
12.4.3. IL-1
12.4.4. IL-5
12.4.5. IL-6
12.4.6.
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Interleukin Inhibitors Market Size and Volume Forecast by Applications
12.7.1. Psoriasis
12.7.2. Psoriatic Arthritis
12.7.3. Rheumatoid Arthritis
12.7.4. Asthma
12.7.5. Inflammatory Bowel Disease (IBD)
12.7.6.
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Interleukin Inhibitors Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Interleukin Inhibitors Market: Market Share Analysis
13.2. Interleukin Inhibitors Distributors and Customers
13.3. Interleukin Inhibitors Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Johnson & Johnson Services, Inc.
13.4.2. Novartis AG
13.4.3. AbbVie Inc.
13.4.4. Eli Lilly and Company
13.4.5. Regeneron Pharmaceuticals, Inc.
13.4.6. AstraZeneca
13.4.7. Bausch Health
13.4.8. F. Hoffmann-La Roche Ltd.
13.4.9. GlaxoSmithKline plc.
13.4.10. Teva Pharmaceuticals Industries, Ltd.&l
2. Assumptions and Acronyms Used
3. Research Methodology
4. Interleukin Inhibitors Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Interleukin Inhibitors Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Interleukin Inhibitors Market - Supply Chain
4.5. Global Interleukin Inhibitors Market Forecast
4.5.1. Interleukin Inhibitors Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Interleukin Inhibitors Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Interleukin Inhibitors Market Absolute $ Opportunity
5. Global Interleukin Inhibitors Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Interleukin Inhibitors Market Size and Volume Forecast by Types
5.3.1. IL-17
5.3.2. IL-23
5.3.3. IL-1
5.3.4. IL-5
5.3.5. IL-6
5.3.6.
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Interleukin Inhibitors Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Interleukin Inhibitors Market Size and Volume Forecast by Applications
6.3.1. Psoriasis
6.3.2. Psoriatic Arthritis
6.3.3. Rheumatoid Arthritis
6.3.4. Asthma
6.3.5. Inflammatory Bowel Disease (IBD)
6.3.6.
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Interleukin Inhibitors Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Interleukin Inhibitors Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Interleukin Inhibitors Demand Share Forecast, 2019-2026
8. North America Interleukin Inhibitors Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Interleukin Inhibitors Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Interleukin Inhibitors Market Size and Volume Forecast by Types
8.4.1. IL-17
8.4.2. IL-23
8.4.3. IL-1
8.4.4. IL-5
8.4.5. IL-6
8.4.6.
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. North America Interleukin Inhibitors Market Size and Volume Forecast by Applications
8.7.1. Psoriasis
8.7.2. Psoriatic Arthritis
8.7.3. Rheumatoid Arthritis
8.7.4. Asthma
8.7.5. Inflammatory Bowel Disease (IBD)
8.7.6.
8.8. Basis Point Share (BPS) Analysis by Applications
8.9. Y-o-Y Growth Projections by Applications
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Interleukin Inhibitors Demand Share Forecast, 2019-2026
9. Latin America Interleukin Inhibitors Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Interleukin Inhibitors Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Interleukin Inhibitors Market Size and Volume Forecast by Types
9.4.1. IL-17
9.4.2. IL-23
9.4.3. IL-1
9.4.4. IL-5
9.4.5. IL-6
9.4.6.
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Latin America Interleukin Inhibitors Market Size and Volume Forecast by Applications
9.7.1. Psoriasis
9.7.2. Psoriatic Arthritis
9.7.3. Rheumatoid Arthritis
9.7.4. Asthma
9.7.5. Inflammatory Bowel Disease (IBD)
9.7.6.
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Interleukin Inhibitors Demand Share Forecast, 2019-2026
10. Europe Interleukin Inhibitors Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Interleukin Inhibitors Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Interleukin Inhibitors Market Size and Volume Forecast by Types
10.4.1. IL-17
10.4.2. IL-23
10.4.3. IL-1
10.4.4. IL-5
10.4.5. IL-6
10.4.6.
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Europe Interleukin Inhibitors Market Size and Volume Forecast by Applications
10.7.1. Psoriasis
10.7.2. Psoriatic Arthritis
10.7.3. Rheumatoid Arthritis
10.7.4. Asthma
10.7.5. Inflammatory Bowel Disease (IBD)
10.7.6.
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Interleukin Inhibitors Demand Share Forecast, 2019-2026
11. Asia Pacific Interleukin Inhibitors Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Interleukin Inhibitors Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Interleukin Inhibitors Market Size and Volume Forecast by Types
11.4.1. IL-17
11.4.2. IL-23
11.4.3. IL-1
11.4.4. IL-5
11.4.5. IL-6
11.4.6.
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Asia Pacific Interleukin Inhibitors Market Size and Volume Forecast by Applications
11.7.1. Psoriasis
11.7.2. Psoriatic Arthritis
11.7.3. Rheumatoid Arthritis
11.7.4. Asthma
11.7.5. Inflammatory Bowel Disease (IBD)
11.7.6.
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Interleukin Inhibitors Demand Share Forecast, 2019-2026
12. Middle East & Africa Interleukin Inhibitors Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Interleukin Inhibitors Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Interleukin Inhibitors Market Size and Volume Forecast by Types
12.4.1. IL-17
12.4.2. IL-23
12.4.3. IL-1
12.4.4. IL-5
12.4.5. IL-6
12.4.6.
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Middle East & Africa Interleukin Inhibitors Market Size and Volume Forecast by Applications
12.7.1. Psoriasis
12.7.2. Psoriatic Arthritis
12.7.3. Rheumatoid Arthritis
12.7.4. Asthma
12.7.5. Inflammatory Bowel Disease (IBD)
12.7.6.
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Interleukin Inhibitors Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Interleukin Inhibitors Market: Market Share Analysis
13.2. Interleukin Inhibitors Distributors and Customers
13.3. Interleukin Inhibitors Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. Johnson & Johnson Services, Inc.
13.4.2. Novartis AG
13.4.3. AbbVie Inc.
13.4.4. Eli Lilly and Company
13.4.5. Regeneron Pharmaceuticals, Inc.
13.4.6. AstraZeneca
13.4.7. Bausch Health
13.4.8. F. Hoffmann-La Roche Ltd.
13.4.9. GlaxoSmithKline plc.
13.4.10. Teva Pharmaceuticals Industries, Ltd.&l
Our Clients
Related Reports
Some other reports from this category!
